| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1021506046 |
| P356 | DOI | 10.1186/1471-2202-8-102 |
| P932 | PMC publication ID | 2233633 |
| P698 | PubMed publication ID | 18045479 |
| P5875 | ResearchGate publication ID | 5803377 |
| P50 | author | Ted M. Dawson | Q56046960 |
| Darren J Moore | Q87693446 | ||
| Valina L. Dawson | Q30505388 | ||
| Andrew B. West | Q37378096 | ||
| P2093 | author name string | Alexis Rea | |
| Saskia Biskup | |||
| Candice E Coombes | |||
| Bettina Lorenz-Deperieux | |||
| P2860 | cites work | Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain | Q48372083 |
| LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain. | Q48645605 | ||
| A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. | Q54683068 | ||
| LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. | Q55041570 | ||
| LRRK2 protein is a component of lewy bodies | Q57341629 | ||
| Evaluation of LRRK2 G2019S penetrance: Relevance for genetic counseling in Parkinson disease | Q62128619 | ||
| The Parkinson disease gene LRRK2: evolutionary and structural insights | Q80243997 | ||
| Genetics of Parkinson's disease | Q80345832 | ||
| Genetics of Parkinson's disease | Q81242038 | ||
| Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity | Q22254785 | ||
| The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity | Q24297634 | ||
| The familial Parkinsonism gene LRRK2 regulates neurite process morphology | Q24317613 | ||
| Localization of LRRK2 to membranous and vesicular structures in mammalian brain | Q24318643 | ||
| Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity | Q24338647 | ||
| Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology | Q28131833 | ||
| Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease | Q28292932 | ||
| A common LRRK2 mutation in idiopathic Parkinson's disease | Q28304886 | ||
| Leucine-rich repeat kinase 2 associates with lipid rafts | Q28591286 | ||
| Kinase activity is required for the toxic effects of mutant LRRK2/dardarin | Q29620478 | ||
| Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations | Q33942173 | ||
| Roc, a Ras/GTPase domain in complex proteins | Q34280792 | ||
| Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1. | Q34613694 | ||
| Molecular pathophysiology of Parkinson's disease | Q36196507 | ||
| Genetics of Parkinson's disease and parkinsonism | Q36636210 | ||
| Deciphering the role of heterozygous mutations in genes associated with parkinsonism | Q36854642 | ||
| G2019S LRRK2 mutation in French and North African families with Parkinson's disease | Q39171895 | ||
| A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease | Q40111589 | ||
| Biochemical and pathological characterization of Lrrk2. | Q40324969 | ||
| LRRK2 expression in normal and pathologic human brain and in human cell lines | Q45302732 | ||
| Distribution of PINK1 and LRRK2 in rat and mouse brain | Q45859017 | ||
| Lrrk2 and Lewy body disease | Q46912096 | ||
| Anatomical localization of leucine-rich repeat kinase 2 in mouse brain | Q46965681 | ||
| LRRK2 expression linked to dopamine-innervated areas | Q46987594 | ||
| Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain | Q48162781 | ||
| Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation | Q48346363 | ||
| P304 | page(s) | 102 | |
| P577 | publication date | 2007-11-28 | |
| P1433 | published in | BMC Neuroscience | Q15766477 |
| P1476 | title | Dynamic and redundant regulation of LRRK2 and LRRK1 expression | |
| P478 | volume | 8 |
| Q41776543 | A Link between Autophagy and the Pathophysiology of LRRK2 in Parkinson's Disease |
| Q35176338 | A comparative study of Lrrk2 function in primary neuronal cultures |
| Q38044445 | A link between LRRK2, autophagy and NAADP-mediated endolysosomal calcium signalling |
| Q37402225 | Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease |
| Q47620111 | Age-Dependent Dopaminergic Neurodegeneration and Impairment of the Autophagy-Lysosomal Pathway in LRRK-Deficient Mice |
| Q37080018 | Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation |
| Q42369410 | Altered Expression of EPO Might Underlie Hepatic Hemangiomas in LRRK2 Knockout Mice. |
| Q35172817 | Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities |
| Q59137953 | Brain injury induces HIF-1α-dependent transcriptional activation of LRRK2 that exacerbates brain damage |
| Q36929535 | Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies |
| Q37479332 | Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization |
| Q37093206 | Developing tTA transgenic rats for inducible and reversible gene expression |
| Q41812724 | Development of an enzyme-linked immunosorbent assay for detection of cellular and in vivo LRRK2 S935 phosphorylation |
| Q46777308 | Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. |
| Q41857057 | Emerging role of LRRK2 in human neural progenitor cell cycle progression, survival and differentiation |
| Q34723024 | Expression analysis of Lrrk1, Lrrk2 and Lrrk2 splice variants in mice |
| Q42201784 | Expression of the LRRK2 gene in the midbrain dopaminergic neurons of the substantia nigra |
| Q34646937 | FIH-1 disrupts an LRRK1/EGFR complex to positively regulate keratinocyte migration |
| Q24339009 | G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization |
| Q21144926 | GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1 |
| Q33346009 | Genes associated with Parkinson syndrome |
| Q38044428 | Genetic analysis of Parkinson's disease-linked leucine-rich repeat kinase 2 |
| Q24310262 | Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment |
| Q38044437 | Human leucine-rich repeat kinase 1 and 2: intersecting or unrelated functions? |
| Q42005064 | LRRK2 and RAB7L1 coordinately regulate axonal morphology and lysosome integrity in diverse cellular contexts. |
| Q58745072 | LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis |
| Q38689010 | LRRK2 at the Crossroad Between Autophagy and Microtubule Trafficking: Insights into Parkinson's Disease. |
| Q24292798 | LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool |
| Q37608630 | LRRK2 in Parkinson's disease: function in cells and neurodegeneration |
| Q37608626 | LRRK2 in Parkinson's disease: in vivo models and approaches for understanding pathogenic roles |
| Q35164433 | LRRK2 is involved in the IFN-gamma response and host response to pathogens |
| Q48693369 | LRRK2 knockdown in zebrafish causes developmental defects, neuronal loss, and synuclein aggregation |
| Q30524899 | LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors |
| Q38253871 | LRRK2 pathobiology in Parkinson's disease |
| Q42149865 | LRRK2 secretion in exosomes is regulated by 14-3-3. |
| Q90269970 | Leucine-Rich Repeat Kinase 2 Controls Inflammatory Cytokines Production through NF-κB Phosphorylation and Antigen Presentation in Bone Marrow-Derived Dendritic Cells |
| Q38977031 | Leucine-rich repeat kinase 2 and Parkinson's disease |
| Q35766417 | Leucine-rich repeat kinase 2 deficiency is protective in rhabdomyolysis-induced kidney injury. |
| Q37294382 | Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions |
| Q34259058 | Leucine-rich repeat kinase 2 for beginners: six key questions. |
| Q37225356 | Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions |
| Q39417130 | Leucine-rich repeat kinase-1 regulates osteoclast function by modulating RAC1/Cdc42 Small GTPase phosphorylation and activation |
| Q35811884 | Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway |
| Q28507051 | Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice |
| Q36325784 | Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau. |
| Q37996364 | Mechanisms of LRRK2-Mediated Neurodegeneration |
| Q33920691 | Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy |
| Q30487210 | Multiple genes on chromosome 7 regulate dopaminergic amacrine cell number in the mouse retina |
| Q37424089 | Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons |
| Q27312569 | No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts |
| Q33797449 | Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis |
| Q36037105 | Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures |
| Q99238235 | Pharmacodynamic Biomarkers for Emerging LRRK2 Therapeutics |
| Q37325908 | RISC in PD: the impact of microRNAs in Parkinson's disease cellular and molecular pathogenesis |
| Q39322027 | Regulation of LRRK2 promoter activity and gene expression by Sp1. |
| Q37697750 | Role and mechanism of action of leucine-rich repeat kinase 1 in bone |
| Q37139305 | Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease |
| Q41978493 | Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice. |
| Q28505157 | Targeted disruption of leucine-rich repeat kinase 1 but not leucine-rich repeat kinase 2 in mice causes severe osteopetrosis |
| Q27007413 | Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic |
| Q91635012 | The Emerging Functions of LRRK2 and Rab GTPases in the Endolysosomal System |
| Q64864674 | The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition |
| Q64287014 | The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A |
| Q24322792 | The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro |
| Q52374337 | The Role of LRRK2 in Neurodegeneration of Parkinson Disease |
| Q37513500 | The function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research |
| Q38202872 | The role of autophagy in Crohn's disease |
| Q42116736 | The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease |
| Q64765285 | Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory- and oxidative stress-related pathways upon treatment with α-synuclein fibrils |
| Q37395783 | Update on the functional biology of Lrrk2. |
| Q37313530 | Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. |
Search more.